230 related articles for article (PubMed ID: 2714889)
1. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity.
Meyer T; Regenass U; Fabbro D; Alteri E; Rösel J; Müller M; Caravatti G; Matter A
Int J Cancer; 1989 May; 43(5):851-6. PubMed ID: 2714889
[TBL] [Abstract][Full Text] [Related]
2. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251.
Andrejauskas-Buchdunger E; Regenass U
Cancer Res; 1992 Oct; 52(19):5353-8. PubMed ID: 1394140
[TBL] [Abstract][Full Text] [Related]
3. Effects of a new protein kinase C inhibitor CGP 41251 on T cell functions: inhibition of activation, growth, and target cell killing.
Alkan SS; Rutschmann S; Grogg D; Erb P
Cell Immunol; 1993 Aug; 150(1):137-48. PubMed ID: 8102085
[TBL] [Abstract][Full Text] [Related]
4. Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation.
Courage C; Budworth J; Gescher A
Br J Cancer; 1995 Apr; 71(4):697-704. PubMed ID: 7710931
[TBL] [Abstract][Full Text] [Related]
5. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance.
Utz I; Hofer S; Regenass U; Hilbe W; Thaler J; Grunicke H; Hofmann J
Int J Cancer; 1994 Apr; 57(1):104-10. PubMed ID: 7908658
[TBL] [Abstract][Full Text] [Related]
6. CGP 41251 and tamoxifen selectively inhibit mitogen-activated protein kinase activation and c-Fos phosphoprotein induction by substance P in human astrocytoma cells.
Luo W; Sharif TR; Houghton PJ; Sharif M
Cell Growth Differ; 1997 Nov; 8(11):1225-40. PubMed ID: 9372245
[TBL] [Abstract][Full Text] [Related]
7. Staurosporine, a novel protein kinase inhibitor, enhances HL-60-cell differentiation induced by various compounds.
Okazaki T; Kato Y; Mochizuki T; Tashima M; Sawada H; Uchino H
Exp Hematol; 1988 Jan; 16(1):42-8. PubMed ID: 2826200
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter.
Begemann M; Kashimawo SA; Choi YA; Kim S; Christiansen KM; Duigou G; Mueller M; Schieren I; Ghosh S; Fabbro D; Lampen NM; Heitjan DF; Schiff PB; Bruce JN; Weinstein IB
Clin Cancer Res; 1996 Jun; 2(6):1017-30. PubMed ID: 9816263
[TBL] [Abstract][Full Text] [Related]
9. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C.
Jarvis WD; Turner AJ; Povirk LF; Traylor RS; Grant S
Cancer Res; 1994 Apr; 54(7):1707-14. PubMed ID: 7511048
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of chemotactic peptide-induced development of cell polarity and locomotion by the protein kinase C inhibitor CGP 41 251 in human neutrophils correlates with inhibition of protein phosphorylation.
Niggli V; Keller H
Exp Cell Res; 1993 Feb; 204(2):346-55. PubMed ID: 8440331
[TBL] [Abstract][Full Text] [Related]
11. Influence of staurosporine, a more selective derivative CGP 41,251 and an inactive analogue CGP 42,700 on histamine release from isolated rat mast cells.
Grosman N
Immunopharmacology; 1992; 24(1):47-55. PubMed ID: 1280632
[TBL] [Abstract][Full Text] [Related]
12. Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue.
Seynaeve CM; Kazanietz MG; Blumberg PM; Sausville EA; Worland PJ
Mol Pharmacol; 1994 Jun; 45(6):1207-14. PubMed ID: 8022414
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of invasion of invasive human bladder carcinoma cells by protein kinase C inhibitor staurosporine.
Schwartz GK; Redwood SM; Ohnuma T; Holland JF; Droller MJ; Liu BC
J Natl Cancer Inst; 1990 Nov; 82(22):1753-6. PubMed ID: 2231770
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of novel human lung carcinoma cell lines selected for resistance to anti-neoplastic analogues of staurosporine.
Courage C; Bradder SM; Jones T; Schultze-Mosgau MH; Gescher A
Int J Cancer; 1997 Nov; 73(5):763-8. PubMed ID: 9398059
[TBL] [Abstract][Full Text] [Related]
15. Effects of protein kinase C inhibitor, staurosporine derivative CGP 41 251, on cell cycle, DNA synthesis and drug uptake in neoplastic cell lines.
Sedlak J; Hunakova L; Duraj J; Chorvath B; Novotny L
Anticancer Drugs; 1995 Feb; 6(1):70-6. PubMed ID: 7756686
[TBL] [Abstract][Full Text] [Related]
16. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells.
Budworth J; Davies R; Malkhandi J; Gant TW; Ferry DR; Gescher A
Br J Cancer; 1996 May; 73(9):1063-8. PubMed ID: 8624264
[TBL] [Abstract][Full Text] [Related]
17. A high throughput system for the evaluation of protein kinase C inhibitors based on Elk1 transcriptional activation in human astrocytoma cells.
Sharif TR; Sharif M
Int J Oncol; 1999 Feb; 14(2):327-35. PubMed ID: 9917510
[TBL] [Abstract][Full Text] [Related]
18. Differential inhibition of cytosolic and membrane-derived protein kinase C activity by staurosporine and other kinase inhibitors.
Budworth J; Gescher A
FEBS Lett; 1995 Apr; 362(2):139-42. PubMed ID: 7536688
[TBL] [Abstract][Full Text] [Related]
19. Differential inhibition of histamine release from mast cells by protein kinase C inhibitors: staurosporine and K-252a.
White JR; Zembryki D; Hanna N; Mong S
Biochem Pharmacol; 1990 Aug; 40(3):447-56. PubMed ID: 1696482
[TBL] [Abstract][Full Text] [Related]
20. Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity.
Begemann M; Kashimawo SA; Heitjan DF; Schiff PB; Bruce JN; Weinstein IB
Anticancer Res; 1998; 18(4A):2275-82. PubMed ID: 9703866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
